Combination therapy with risedronate and teriparatide in male osteoporosis

Endocrine

Volumn 44, Issue 1, 2013, Pages 237-246

  Walker, Marcella D ^a   Cusano, Natalie E ^a   Sliney Jr , James ^a   Romano, Megan ^a   Zhang, Chiyuan ^a   McMahon, Donald J ^a   Bilezikian, John P ^a  

^a Columbia University ^*  (United States)

Author keywords

Bone mineral density; Combination therapy; Male osteoporosis; Risedronate; Teriparatide

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; PARATHYROID HORMONE[1-34]; PROPEPTIDE OF TYPE I COLLAGEN; RISEDRONIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DYSPHAGIA; FATIGUE; FEMUR NECK; GASTROESOPHAGEAL REFLUX; HIP; HUMAN; INJECTION SITE IRRITATION; LEG CRAMP; LUMBAR SPINE; MALE; MALE OSTEOPOROSIS; MONOTHERAPY; NEPHROLITHIASIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ETIDRONIC ACID; FEMUR NECK; HUMANS; INJECTIONS, SUBCUTANEOUS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOPOROSIS; PLACEBOS; TERIPARATIDE;

EID: 84881125567     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-012-9819-4     Document Type: Article

References (27)

1. R. Eastell, I.T. Boyle, J. Compston, C. Cooper, I. Fogelman, R.M. Francis, D.J. Hosking, D.W. Purdie, S. Ralston, J. Reeve, D.M. Reid, R.G. Russell, J.C. Stevenson, Management of male osteoporosis: report of the UK Consensus Group. QJM 91(2), 71-92 (1998)
2. O. Johnell, J.A. Kanis, An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int. 17(12), 1726-1733 (2006). doi: 10.1007/s00198-006-0172-4
3. J.R. Center, T.V. Nguyen, D. Schneider, P.N. Sambrook, J.A. Eisman, Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353(9156), 878-882 (1999). doi: 10.1016/S0140- 6736(98)09075-8
4. J.A. Kanis, G. Bianchi, J.P. Bilezikian, J.M. Kaufman, S. Khosla, E. Orwoll, E. Seeman, Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos. Int. 22(11), 2789-2798 (2011). doi: 10.1007/s00198-011-1632-z
5. E.S. Kurland, F. Cosman, D.J. McMahon, C.J. Rosen, R. Lindsay, J.P. Bilezikian, Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J. Clin. Endocrinol. Metab. 85(9), 3069-3076 (2000)
6. E.S. Orwoll, W.H. Scheele, S. Paul, S. Adami, U. Syversen, A. Diez-Perez, J.M. Kaufman, A.D. Clancy, G.A. Gaich, The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res. 18(1), 9-17 (2003). doi: 10.1359/jbmr.2003.18.1.9
7. E. Orwoll, M. Ettinger, S. Weiss, P. Miller, D. Kendler, J. Graham, S. Adami, K. Weber, R. Lorenc, P. Pietschmann, K. Vandormael, A. Lombardi, Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. 343(9), 604-610 (2000). doi: 10.1056/NEJM200008313430902
8. S. Boonen, E.S. Orwoll, D. Wenderoth, K.J. Stoner, R. Eusebio, P.D. Delmas, Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J. Bone Miner. Res. 24(4), 719-725 (2009). doi: 10.1359/jbmr.081214
9. E.S. Orwoll, P.D. Miller, J.D. Adachi, J. Brown, R.A. Adler, D. Kendler, C. Bucci-Rechtweg, A. Readie, P. Mesenbrink, R.S. Weinstein, Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J. Bone Miner. Res. 25(10), 2239-2250 (2010). doi: 10.1002/jbmr.119
10. G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41(1), 58-69 (2012). doi: 10.1007/s12020-011-9570-2
11. J.S. Finkelstein, A. Hayes, J.L. Hunzelman, J.J. Wyland, H. Lee, R.M. Neer, The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 349(13), 1216-1226 (2003). doi: 10.1056/NEJMoa035725NEJMoa035725
12. J.S. Finkelstein, B.Z. Leder, S.M. Burnett, J.J. Wyland, H. Lee, A.V. de la Paz, K. Gibson, R.M. Neer, Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J. Clin. Endocrinol. Metab. 91(8), 2882-2887 (2006). doi: 10.1210/jc.2006-0190
13. J.S. Finkelstein, J.J. Wyland, H. Lee, R.M. Neer, Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 95(4), 1838-1845 (2010). doi: 10.1210/jc.2009-1703
14. D.M. Black, S.L. Greenspan, K.E. Ensrud, L. Palermo, J.A. McGowan, T.F. Lang, P. Garnero, M.L. Bouxsein, J.P. Bilezikian, C.J. Rosen, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349(13), 1207-1215 (2003). doi: 10.1056/NEJMoa031975NEJMoa031975
15. J. Compston, The use of combination therapy in the treatment of postmenopausal osteoporosis. Endocrine 41(1), 11-18 (2012). doi: 10.1007/s12020-011-9554-2
16. C. Deal, M. Omizo, E.N. Schwartz, E.F. Eriksen, P. Cantor, J. Wang, E.V. Glass, S.L. Myers, J.H. Krege, Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J. Bone Miner. Res. 20(11), 1905-1911 (2005). doi: 10.1359/JBMR.050714
17. G.H. Nancollas, R. Tang, R.J. Phipps, Z. Henneman, S. Gulde, W. Wu, A. Mangood, R.G. Russell, F.H. Ebetino, Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38(5), 617-627 (2006). doi: 10.1016/j.bone.2005.05.003
18. C.J. Rosen, M.C. Hochberg, S.L. Bonnick, M. McClung, P. Miller, S. Broy, R. Kagan, E. Chen, R.A. Petruschke, D.E. Thompson, A.E. de Papp, Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J. Bone Miner. Res. 20(1), 141-151 (2005). doi: 10.1359/JBMR.040920
19. S.L. Bonnick, C.C. Johnston Jr, M. Kleerekoper, R. Lindsay, P. Miller, L. Sherwood, E. Siris, Importance of precision in bone density measurements. J Clin Densitom 4(2), 105-110 (2001)
20. H.K. Genant, C.Y. Wu, C. van Kuijk, M.C. Nevitt, Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 8(9), 1137-1148 (1993). doi: 10.1002/jbmr.5650080915
21. F. Cosman, E.F. Eriksen, C. Recknor, P.D. Miller, N. Guanabens, C. Kasperk, P. Papanastasiou, A. Readie, H. Rao, J.A. Gasser, C. Bucci-Rechtweg, S. Boonen, Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J. Bone Miner. Res. 26(3), 503-511 (2011). doi: 10.1002/jbmr.238
22. R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, A.B. Hodsman, E.F. Eriksen, S. Ish-Shalom, H.K. Genant, O. Wang, B.H. Mitlak, Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344(19), 1434-1441 (2001)
23. B. Borah, T. Dufresne, J. Nurre, R. Phipps, P. Chmielewski, L. Wagner, M. Lundy, M. Bouxsein, R. Zebaze, E. Seeman, Risedronate reduces intracortical porosity in women with osteoporosis. J. Bone Miner. Res. 25(1), 41-47 (2010). doi: 10.1359/jbmr.090711
24. P.D. Miller, P.D. Delmas, R. Lindsay, N.B. Watts, M. Luckey, J. Adachi, K. Saag, S.L. Greenspan, E. Seeman, S. Boonen, S. Meeves, T.F. Lang, J.P. Bilezikian, Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J. Clin. Endocrinol. Metab. 93(10), 3785-3793 (2008). doi: 10.1210/jc.2008-0353
25. D. Gatti, O. Viapiana, S. Adami, L. Idolazzi, E. Fracassi, M. Rossini, Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 50(3), 739-742 (2012). doi: 10.1016/j.bone.2011.11.028
26. S.A. Polyzos, A.D. Anastasilakis, C. Bratengeier, W. Woloszczuk, A. Papatheodorou, E. Terpos, Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women - the six-month effect of risedronate and teriparatide. Osteoporos. Int. 23(3), 1171-1176 (2012). doi: 10.1007/s00198-010-1525-6
27. J.F. Griffith, H.K. Genant, New advances in imaging osteoporosis and its complications. Endocrine 42(1), 39-51 (2012). doi: 10.1007/s12020-012-9691-2